You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Bruker Corporation completed a reportable segment reorganization effective July 1, 2026, creating BSI BIOS and BSI Microbiology and Infection Diagnostics while retaining BSI NANO and BEST. Recast historical segment data has no impact on consolidated results, financial position or cash flows.
Bruker Corporation reported quarterly revenue of $874.0 million, up 1.6%, and non-GAAP operating income of $142.6 million. A $174.5 million goodwill impairment within BSI NANO drove a $91.0 million GAAP operating loss.
Bruker Corporation posted Q3-26 revenue of $874.0 million, up 1.6% yoy, non-GAAP operating margin of 16.3% and non-GAAP diluted EPS of $0.56, up 24.4% yoy. FY26 revenue guidance is $3.52 to $3.56 billion and non-GAAP EPS $2.10 to $2.15.
Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, payable December 1, 2026, to shareholders of record November 15, 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Bruker delivered substantial non-GAAP margin and EPS growth, positive BSI bookings and backlog, reconfirmed FY26 EPS guidance, improved free cash flow, and debt reduction with net leverage below its target. The main concerns were GAAP diluted losses, soft organic and BSI revenue, currency headwinds, semiconductor metrology push-outs, and weaker Asia-Pacific revenue.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP CER currency revenue non-GAAP | $831.5M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP revenue 838.5M
-7M Effect of changes in foreign currency translation rates
= Non-GAAP CER currency revenue 831.5M
|
|||
| Non-GAAP Organic Revenue non-GAAP | $820.1M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationNon-GAAP CER currency revenue 831.5M (the result of another reconciliation in this filing)
-11.4M Acquisitions
= Non-GAAP Organic revenue 820.1M
|
|||
| BSI bookings organic year-over-year growth non-GAAP | 10% | Q2-26 | — |
| Non-GAAP CER currency revenue year-on-year growth rate non-GAAP | 1.2% | Six Months Ended June 30, 2026 | — |
| Non-GAAP free cash flow non-GAAP | -$59.2M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating (Loss) Income Margin non-GAAP | 14.1% | Three Months Ended June 30, 2026 | — |
| Non-GAAP Operating Income non-GAAP | $202.7M | First Half 2026 | — |
| Non-GAAP Operating Income Margin non-GAAP | 12.2% | First Half 2026 | — |
| Non-GAAP Organic Revenue year-on-year growth rate non-GAAP | 2.8% | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRKR
this stock
Bruker Corp
|
$9.58B | +30.7% | +7.3% | — | 7.2% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Bruker Corporation completed a reportable segment reorganization effective July 1, 2026, creating BSI BIOS and BSI Microbiology and Infection Diagnostics while retaining BSI NANO and BEST. Recast historical segment data has no impact on consolidated results, financial position or cash flows.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRKR | +0.5% | +12.4% | +31.3% | +7.9% | +30.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.1% | +13.6% | +30.8% | +8.1% | +20.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
